SpauldingA. C., KennedyS. S., OseiJ., SidibehE., BatinaI. V., ChhatwalJ., AkiyamaM. J., & StrickL. B. (2023). Estimates of hepatitis C seroprevalence and viremia in state prison populations in the United States. Journal of Infectious Diseases, 228(S3), S160–S167. https://doi.org/10.1093/infdis/jiad227
2.
MoyerV. A., & U.S. Preventive Services Task Force. (2013). Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 159(5), 349–357. https://doi.org/10.7326/0003-4819-159-5-201309030-00672
3.
Centers for Disease Control and Prevention. (2022). At-a-glance: CDC recommendations for correctional and detention settings testing, vaccination, and treatment for HIV, viral hepatitis, TB, and STIs. https://stacks.cdc.gov/view/cdc/120256
4.
American Association for the Study of Liver Diseases/Infectious Diseases Society of America. (n.d.). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org
5.
BhattacharyaD., AronsohnA., PriceJ., Lo ReV., & AASLD-IDSA HCV Guidance Panel. (2023). Hepatitis C guidance 2023 update: AASLD–IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clinical Infectious Diseases, ciad319. https://doi.org/10.1093/cid/ciad319
6.
McNamaraM., FurukawaN., & CartwrightE. J. (2024). Advancing hepatitis C elimination through opt-out universal screening and treatment in carceral settings, United States. Emerging Infectious Diseases, 30(13), S80–S87. https://doi.org/10.3201/eid3013.230859
7.
ThorntonK., SedilloM. L., KalishmanS., PageK., & AroraS. (2018). The New Mexico peer education project: Filling a critical gap in HCV prison education. Journal of Health Care for the Poor and Underserved, 29(4), 1544–1557. https://doi.org/10.1353/hpu.2018.0111
8.
SyedT. A., CherianR., LewisS., & SterlingR. K. (2021). Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals. Journal of Viral Hepatitis, 28(1), 209–212. https://doi.org/10.1111/jvh.13392
9.
ChanJ., KabaF., SchwartzJ., BocourA., AkiyamaM. J., RosnerZ., WintersA., YangP., & MacDonaldR. (2020). The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014–2017. EClinicalMedicine, 27, 100567. https://doi.org/10.1016/j.eclinm.2020.100567
10.
HaleA. J., MathurS., DejaceJ., & LidofskyS. D. (2023). Statewide assessment of the hepatitis C virus care cascade for incarcerated persons in Vermont. Public Health Reports, 138(2), 265–272. https://doi.org/10.1177/00333549221077070
11.
AroraS., ThorntonK., MurataG., DemingP., KalishmanS., DionD., ParishB., BurkeT., PakW., DunkelbergJ., KistinM., BrownJ., JenkuskyS., KomaromyM., & QuallsC. (2011). Outcomes of treatment for hepatitis C virus infection by primary care providers. New England Journal of Medicine, 364(23), 2199–2207. https://doi.org/10.1056/NEJMoa1009370
12.
HajarizadehB., CunninghamE. B., ValerioH., MartinelloM., LawM., JanjuaN. Z., MidgardH., DalgardO., DillonJ., HickmanM., BruneauJ., DoreG. J., & GrebelyJ. (2020). Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 72(4), 643–657. https://doi.org/10.1016/j.jhep.2019.11.012
13.
FleurenceR. L., & CollinsF. S. (2023). A national hepatitis C elimination program in the United States: A historic opportunity. JAMA, 329(15), 1251–1252. https://doi.org/10.1001/jama.2023.3692
